Lariciresinol

Lariciresinol is an orally active ingredient. Lariciresinol can be isolated from Arabidopsis thaliana. Lariciresinol inhibits α-glucosidase activity (IC₅₀ of 6.97 μM; K_i of 0.046 μM). Lariciresinol dereases Bcl-2, upregulates Bax and induces Apoptosis. Lariciresinol regulates TGF-β and NF-κB pathways. Lariciresinol has antitumor activity against liver cancer, gastric cancer, and breast cancer. Lariciresinol shows antifungal activity and anti-diabetic activity^{[1][2][3][4][5][6][7][8]}. In Vitro: Lariciresinol (100-400 µg/mL, 24-72 h) induces apoptosis in HepG2 cells via mitochondrial-mediated apoptosis pathway^[2].
Lariciresinol (72 h) induces morphological changes, decreases cell growth, survival, proliferation and increases apoptosis in SKBr3 cells^[3].
Lariciresinol (10-40 µM, 24 h) inhibits migration-invasion of patient-derived hypertrophic scar fibroblasts via preventing accumulation of collagen^[4].
Lariciresinol shows antifungal activity against C. albicans, T. beigelii, and M. furfur with MIC values of 25, 12.5 and 25 μg/mL, respectively^[5].
Lariciresinol inhibits α-glucosidase activity with an IC50 value of 6.97 µM and a Ki value of 0.046 µM^[6].
Lariciresinol activates insulin signaling leading to glucose transporter 4 (GLUT4) translocation and augmentes glucose uptake in C2C12 cells^[6].
In Vivo: Lariciresinol (10 mg/kg, p.o., 3 weeks) displays anti-diabetic activity in Streptozotocin (HY-13753)-treated diabetic mice^[6].
Lariciresinol (10-30 mg/kg, i.p., 28 days) inhibits complete Freund's adjuvant-induced arthritis in rats by regulating TGF-β and NF-κB pathways^[7].
Lariciresinol (3-15 mg/kg body weight, p.o., daily, 9 weeks (tumor bearing rats); 20-100 ppm, diet, p.o., 5 weeks (E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors)) inhibits tumor growth and tumor angiogenesis in mammary tumor bearing rats and E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors^[8].